The Asia Pacific Opioid Use Disorder (OUD) Market should witness market growth of 10.9% CAGR during the forecast period (2023-2030).
One of the main drivers propelling the market is the rise in the number of drugs approved for treating opioid use disorder, the rise in opioid addiction cases in developed nations, and the growing acceptance of buprenorphine patches as a viable treatment option. Every year, there are an increasing number of cases of opioid addiction, making opioid dependency a severe public health concern. In order to reduce the perception of pain, opioids interact with opioid receptors in the body and the brain. Opioids can be either natural, semi-natural, or synthetic chemicals.
According to the Indian government, the country's opioid consumption problems (harmful use and dependency) is predicted to affect 2.06% of Indians overall and 0.55% of Indians individually. Heroin dependence is greater than that of opium and pharmaceutical opioid dependence. Only several states - Uttar Pradesh, Punjab, Haryana, Delhi, Maharashtra, Rajasthan, Andhra Pradesh, and Gujarat - contribute more than half of the estimated 60 lakh people with opioid use disorders (harmful or dependent pattern) in the nation. There are approximately 40,00,000 opioid users overall in India between the ages of 10 and 17 and 1,86,440,000 between the ages of 18 and 75.
China has serious drug misuse concerns that seem to be getting worse over time. Because of its severe medical effects, impact on risk for HIV/AIDS and criminal behavior, poor rates of recovery, and high rates of relapse, opiate use seriously threatens China's public health and social security. MMT and other cutting-edge treatments for opiate addiction are essential to be adopted in the nation. Thus, the market for opioid use disorders is expanding due to the rising prevalence of opioid drugs and addiction.
The China market dominated the Asia Pacific Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $422.7 million by 2030. The Japan market is poised to grow at a CAGR of 10.1% during (2023-2030). Additionally, The India market would display a CAGR of 11.4% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
One of the main drivers propelling the market is the rise in the number of drugs approved for treating opioid use disorder, the rise in opioid addiction cases in developed nations, and the growing acceptance of buprenorphine patches as a viable treatment option. Every year, there are an increasing number of cases of opioid addiction, making opioid dependency a severe public health concern. In order to reduce the perception of pain, opioids interact with opioid receptors in the body and the brain. Opioids can be either natural, semi-natural, or synthetic chemicals.
According to the Indian government, the country's opioid consumption problems (harmful use and dependency) is predicted to affect 2.06% of Indians overall and 0.55% of Indians individually. Heroin dependence is greater than that of opium and pharmaceutical opioid dependence. Only several states - Uttar Pradesh, Punjab, Haryana, Delhi, Maharashtra, Rajasthan, Andhra Pradesh, and Gujarat - contribute more than half of the estimated 60 lakh people with opioid use disorders (harmful or dependent pattern) in the nation. There are approximately 40,00,000 opioid users overall in India between the ages of 10 and 17 and 1,86,440,000 between the ages of 18 and 75.
China has serious drug misuse concerns that seem to be getting worse over time. Because of its severe medical effects, impact on risk for HIV/AIDS and criminal behavior, poor rates of recovery, and high rates of relapse, opiate use seriously threatens China's public health and social security. MMT and other cutting-edge treatments for opiate addiction are essential to be adopted in the nation. Thus, the market for opioid use disorders is expanding due to the rising prevalence of opioid drugs and addiction.
The China market dominated the Asia Pacific Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $422.7 million by 2030. The Japan market is poised to grow at a CAGR of 10.1% during (2023-2030). Additionally, The India market would display a CAGR of 11.4% during (2023-2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC , and Viatris, Inc.
Scope of the Study
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
Chapter 5. Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
Chapter 6. Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 7. Asia Pacific Opioid Use Disorder (OUD) Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Methodology
LOADING...
